Tatyana S. Lutkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tatyana S. Lutkova has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Louise M. Karzakova
I. Ulyanov Chuvash State University
7 shared publications - Nadezhda V. Zhuravleva
Chuvash State University; Chuvashia Med Insurance Company JSC
5 shared publications - Sergei I. Kudryashov
Chuvash State University
3 shared publications - Ukhterova Nadezhda Dmitrievna
Chuvash State University
3 shared publications - Elvira S. Gavrilova
Chuvash State University
2 shared publications - Ivan А. Sidorov
Chuvash State University
2 shared publications
Latest Publications
- 30 March 2026
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 1
The effectiveness of secondary immunodeficiency therapy using bacteriophages: a clinical case
The article is devoted to an urgent problem of practical medicine – secondary immunodeficiencies. In the practice of a primary care physician of any specialty, patients with secondary immunodeficiencies are much more common than those with primary immunodeficiency, but they are extremely rarely diagnosed. To date, there is no official diagnosis "secondary immunodeficiency", which explains why this condition is underdiagnosed and why there are no standardized approaches to its treatment. Secondary immunodeficiencies are known to develop in individuals whose immune systems were initially functioning normally and can manifest at any age. An important clinical sign of secondary immunodeficiency is an increased susceptibility to infectious diseases, caused by a reduction in the number and/or functional activity of immune system cells. Secondary immunodeficiencies most commonly manifest by respiratory diseases affecting the upper respiratory tract, formation of foci of chronic infection: nasopharyngitis, rhinosinusitis, otitis media, tonsillitis. Viral infections mainly inhibit the cellular component of the immune system, reducing the activity of CD4-lymphocytes, and cause an imbalance of cytokines. Frequent, sometimes unjustified prescribing of antibiotics leads to disruption of the intestinal microflora, which can worsen the course of secondary immunodeficiency. The article examines the main causes of secondary immunodeficiency, clinical classification and general approaches to patient management. The importance of a clinical and laboratory examination to clarify the affected link of immunity is shown. As part of the patient’s treatment, immunological parameters and the results of microbiological stool tests were analyzed. A clinical case of a patient with secondary immunodeficiency is described, demonstrating the effectiveness of therapy using bacteriophages.
- 30 March 2026
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 1
The effectiveness of secondary immunodeficiency therapy using bacteriophages: a clinical case
The article is devoted to an urgent problem of practical medicine – secondary immunodeficiencies. In the practice of a primary care physician of any specialty, patients with secondary immunodeficiencies are much more common than those with primary immunodeficiency, but they are extremely rarely diagnosed. To date, there is no official diagnosis "secondary immunodeficiency", which explains why this condition is underdiagnosed and why there are no standardized approaches to its treatment. Secondary immunodeficiencies are known to develop in individuals whose immune systems were initially functioning normally and can manifest at any age. An important clinical sign of secondary immunodeficiency is an increased susceptibility to infectious diseases, caused by a reduction in the number and/or functional activity of immune system cells. Secondary immunodeficiencies most commonly manifest by respiratory diseases affecting the upper respiratory tract, formation of foci of chronic infection: nasopharyngitis, rhinosinusitis, otitis media, tonsillitis. Viral infections mainly inhibit the cellular component of the immune system, reducing the activity of CD4-lymphocytes, and cause an imbalance of cytokines. Frequent, sometimes unjustified prescribing of antibiotics leads to disruption of the intestinal microflora, which can worsen the course of secondary immunodeficiency. The article examines the main causes of secondary immunodeficiency, clinical classification and general approaches to patient management. The importance of a clinical and laboratory examination to clarify the affected link of immunity is shown. As part of the patient’s treatment, immunological parameters and the results of microbiological stool tests were analyzed. A clinical case of a patient with secondary immunodeficiency is described, demonstrating the effectiveness of therapy using bacteriophages.
- Open Access
- 13 June 2023
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 26 (1) , 181-190
A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
Glomerulonephritis (GN) is a group of immuno-inflammatory kidney diseases with predominant glomerular lesions that are difficult to treat. The greatest problems are caused by the treatment of GN with nephrotic syndrome, which often has a recurrent course. The aim of the research was to study the effectiveness of recombinant interleukin-2 (rIL-2) therapy in the GN patients with nephrotic syndrome. 62 patients with a nephrotic form of primary GN with frequent relapses admitted to the Nephrology Department have been recruited into the study. The age of patients was from 18 to 65 years. The patients underwent standard examinations, as well as immunological studies, before administration of the anti-relapse treatment, and 12 months after the treatment was started. Immunological testing included immunophenotyping of lymphocytes with counting of T and B lymphocytes, immunoregulatory and activated subpopulations of T lymphocytes, determination of urinary immunoglobulins (IgM, IgG, IgA) by immunoturbidimetric assays, proinflammatory cytokines – IL-1β, IL-8, IL-17A and anti-inflammatory cytokine IL-10 by ELISA tests. As a result of studies, the examined patients showed an increased contents of T helper cells, activated T lymphocytes (CD8+HLA-DR+CD45+, CD3+CD8brightCD38+) along with decreased numbers of Treg cells and an increased contents of proinflammatory cytokines IL-1β, IL-8, IL-17A and immunoglobulins of all three classes in urinary samples.The cohort of patients with GN selected for the study was divided in two groups (the main group and the comparison group). In addition to nephroprotective and steroid therapy, the treatment regimen of patients included rIL-2 in the main group, or cyclophosphamide in the comparison group. Regardless of the method used, the levels of protein, IgG and IL-17A in the urine proved to be decreased relative to the initial values; the contents of B cells and HLA-DR+ cytotoxic T lymphocytes in peripheral blood were found to be decreased. The revealed changes were more pronounced in the main group of patients. By 12 months after starting the treatment, the mentioned indexes began to differ significantly in the main group from those in the comparison group. Serum creatinine levels, numbers of T helper cells and Treg cells, IL-1β levels in urine did not undergo significant changes in the comparison group, whereas a decrease in serum creatinine and urinary IL-1β was registered in the main group of patients, along with decreased number of T helpers and increased numbers of Treg cells. In the main group of patients treated with rIL-2, the average number of relapses per year decreased by 4 times, showing only a 1.2-fold decrease in the comparison group. Hence, the low-dose therapy with rIL-2 may be considered an effective and safe alternative to conventional immunosuppressive therapy and a new option of the targeted treatment of glomerulonephritis with frequent recurrence of nephrotic syndrome.
- 13 June 2023
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 26 (1) , 181-190
Open AccessA new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
Glomerulonephritis (GN) is a group of immuno-inflammatory kidney diseases with predominant glomerular lesions that are difficult to treat. The greatest problems are caused by the treatment of GN with nephrotic syndrome, which often has a recurrent course. The aim of the research was to study the effectiveness of recombinant interleukin-2 (rIL-2) therapy in the GN patients with nephrotic syndrome. 62 patients with a nephrotic form of primary GN with frequent relapses admitted to the Nephrology Department have been recruited into the study. The age of patients was from 18 to 65 years. The patients underwent standard examinations, as well as immunological studies, before administration of the anti-relapse treatment, and 12 months after the treatment was started. Immunological testing included immunophenotyping of lymphocytes with counting of T and B lymphocytes, immunoregulatory and activated subpopulations of T lymphocytes, determination of urinary immunoglobulins (IgM, IgG, IgA) by immunoturbidimetric assays, proinflammatory cytokines – IL-1β, IL-8, IL-17A and anti-inflammatory cytokine IL-10 by ELISA tests. As a result of studies, the examined patients showed an increased contents of T helper cells, activated T lymphocytes (CD8+HLA-DR+CD45+, CD3+CD8brightCD38+) along with decreased numbers of Treg cells and an increased contents of proinflammatory cytokines IL-1β, IL-8, IL-17A and immunoglobulins of all three classes in urinary samples.The cohort of patients with GN selected for the study was divided in two groups (the main group and the comparison group). In addition to nephroprotective and steroid therapy, the treatment regimen of patients included rIL-2 in the main group, or cyclophosphamide in the comparison group. Regardless of the method used, the levels of protein, IgG and IL-17A in the urine proved to be decreased relative to the initial values; the contents of B cells and HLA-DR+ cytotoxic T lymphocytes in peripheral blood were found to be decreased. The revealed changes were more pronounced in the main group of patients. By 12 months after starting the treatment, the mentioned indexes began to differ significantly in the main group from those in the comparison group. Serum creatinine levels, numbers of T helper cells and Treg cells, IL-1β levels in urine did not undergo significant changes in the comparison group, whereas a decrease in serum creatinine and urinary IL-1β was registered in the main group of patients, along with decreased number of T helpers and increased numbers of Treg cells. In the main group of patients treated with rIL-2, the average number of relapses per year decreased by 4 times, showing only a 1.2-fold decrease in the comparison group. Hence, the low-dose therapy with rIL-2 may be considered an effective and safe alternative to conventional immunosuppressive therapy and a new option of the targeted treatment of glomerulonephritis with frequent recurrence of nephrotic syndrome.
- 30 June 2022
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 2
THE EFFECT OF COVID-19 ON MYOCARDIAL DAMAGE: A CLINICAL CASE
Despite the fact that the general clinical manifestations of COVID-19 are well known, there remain problems associated with the impact of COVID-19 on human health, in addition to its effects on the respiratory system. Patients with COVID-19 and concomitant cardiovascular diseases are more likely to be hospitalized and to pass treatment in the intensive care units and to have worse prognoses. The article discusses the problems arising from the effect of type 2 coronavirus acute respiratory syndrome (SARS-CoV-2) on the cardiovascular system, starting with the mechanisms associated with angiotensin converting enzyme 2 (ACE2) receptors, as well as discusses cases of major pathological changes in the heart and blood vessels that are detected in these patients. In addition to the known risk factors for severe COVID-19: cardiovascular diseases, diabetes mellitus, chronic lung diseases and old age, even young patients without a history of risk factors may develop myocardial damage. We present a description of a clinical case of acute myocardial infarction against the background of a new coronavirus infection COVID-19 in a patient aged 28 years with a diagnosis of coronary heart disease.
- 30 June 2022
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 2
THE EFFECT OF COVID-19 ON MYOCARDIAL DAMAGE: A CLINICAL CASE
Despite the fact that the general clinical manifestations of COVID-19 are well known, there remain problems associated with the impact of COVID-19 on human health, in addition to its effects on the respiratory system. Patients with COVID-19 and concomitant cardiovascular diseases are more likely to be hospitalized and to pass treatment in the intensive care units and to have worse prognoses. The article discusses the problems arising from the effect of type 2 coronavirus acute respiratory syndrome (SARS-CoV-2) on the cardiovascular system, starting with the mechanisms associated with angiotensin converting enzyme 2 (ACE2) receptors, as well as discusses cases of major pathological changes in the heart and blood vessels that are detected in these patients. In addition to the known risk factors for severe COVID-19: cardiovascular diseases, diabetes mellitus, chronic lung diseases and old age, even young patients without a history of risk factors may develop myocardial damage. We present a description of a clinical case of acute myocardial infarction against the background of a new coronavirus infection COVID-19 in a patient aged 28 years with a diagnosis of coronary heart disease.
- 30 September 2021
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 3,p. 60-68
MODERN APPROACHES TO THE DIAGNOSIS AND THERAPY OF ALLERGIC DISEASES
Currently, great efforts are being made to optimize diagnostic and therapeutic standards in allergology. The introduction of biological drugs (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab) into clinical practice increases the need for biomarkers of allergic diseases that make it possible to adequately choose a treatment regimen, determine the duration of therapy with expensive biopreparations. The article discusses the possibilities of using biomarkers developed in recent years thanks to the so-called "omics" technologies in clinical practice. Biomarkers used for the diagnosis and treatment of bronchial asthma, atopic dermatitis, allergic rhinitis, food allergies, hypersensitivity to drugs, as well as for evaluating the effectiveness of allergen – specific immunotherapy are considered. The introduction of biomarkers into clinical practice has made it possible to carry out endotyping of some allergic diseases, which opens up prospects for new approaches to classification of these diseases, development of individual treatment targets and indications for administering personalized therapy. Endotyping of diseases is expected to be transferred to the category of diagnostic tests. However, it is necessary to overcome a number of problems before the treatment based on endotype determination will be introduced into everyday practice in allergic diseases and bronchial asthma. Currently, most of the research on the endotyping of diseases is carried out in severe forms of allergic diseases. It is beyond argument that the best ways to treat allergic diseases will be found in the near future, with a therapeutic approach focused on a specific patient, taking into account the patient's wishes, the presence of contraindications, the psychological characteristics of the patient, his expected adherence to therapy and possible side effects.
- 30 September 2021
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 3,p. 60-68
MODERN APPROACHES TO THE DIAGNOSIS AND THERAPY OF ALLERGIC DISEASES
Currently, great efforts are being made to optimize diagnostic and therapeutic standards in allergology. The introduction of biological drugs (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab) into clinical practice increases the need for biomarkers of allergic diseases that make it possible to adequately choose a treatment regimen, determine the duration of therapy with expensive biopreparations. The article discusses the possibilities of using biomarkers developed in recent years thanks to the so-called "omics" technologies in clinical practice. Biomarkers used for the diagnosis and treatment of bronchial asthma, atopic dermatitis, allergic rhinitis, food allergies, hypersensitivity to drugs, as well as for evaluating the effectiveness of allergen – specific immunotherapy are considered. The introduction of biomarkers into clinical practice has made it possible to carry out endotyping of some allergic diseases, which opens up prospects for new approaches to classification of these diseases, development of individual treatment targets and indications for administering personalized therapy. Endotyping of diseases is expected to be transferred to the category of diagnostic tests. However, it is necessary to overcome a number of problems before the treatment based on endotype determination will be introduced into everyday practice in allergic diseases and bronchial asthma. Currently, most of the research on the endotyping of diseases is carried out in severe forms of allergic diseases. It is beyond argument that the best ways to treat allergic diseases will be found in the near future, with a therapeutic approach focused on a specific patient, taking into account the patient's wishes, the presence of contraindications, the psychological characteristics of the patient, his expected adherence to therapy and possible side effects.
- Open Access
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 969
POS1374 RHEUMATOLOGIC DISEASES AS PRESENTATIONS OF PRIMARY IMMUNODEFICIENCY DISEASES
Background: Primary immunodeficiency diseases (PID) occur on average with a frequency of 1: 100 000 of the population. In accordance with the classification of PIDS of the International Union of Immunological Societies (IUIS) 9 different groups of innate errors of immunity are distinguished [1]. The polymorphism of the clinical picture, difficulties in recognizing PID cause their late diagnosis and the associated development of irreversible organ damage, complications and high mortality. According to the traditional view, the clinical marker of PID is an infectious syndrome. However, in some cases, PID is detected as a rheumatologic disease. Objectives: The aim of the study is to analyze the frequency of rheumatologic diseases in adult patients with PID living in one of the subjects of Russia –Chuvashia. Methods: The material of the study was patient data obtained during a retrospective analysis of 49 outpatient records included in the Republican Register of PID. Diagnosis of various forms of PIDS was carried out in accordance with the criteria developed by the IUIS [1]. Results: During the period from 1993 to January 2020, 49 cases of PID were registered in the adult population of Chuvashia. According to the frequency of PID, сommon variable immunodeficiency (CVID) is the most common in Chuvashia (26 people). In the second place there is selective IgA deficiency (10 people); in third place there are X-linked agammaglobulinemia (4 people) and hereditary angioedema (4 people). The remaining forms of PID account for 5 cases: 2 cases of Louis-Bar syndrome, 1 case of DiGeorge syndrome, 1 case of Wiskott-Aldrich syndrome and 1 case of Hyper IgE syndrome. The main symptom of PID in 35 (71.4%) patients was heightened susceptibility to infection. In 14 (28.6%) patients, the clinical picture was dominated by non-infectious presentations (autoimmune, lymphoproliferative and oncological diseases). In 9 patients (18.3%), it was manifested by rheumatologic diseases (rheumatoid arthritis, psoriatic arthritis, scleroderma-like syndrome). These symptoms were more characteristic of CVID. With selective IgA deficiency and X-linked agammaglobulinemia, rheumatic symptoms were observed only in isolated cases. CVID debuted in 2 cases as rheumatoid arthritis, resulting in the delay in the diagnosis of an average of 5.2 years. Only the detailed immunological and genetic study made it possible to diagnose PID and prescribe adequate treatment – replacement immunoglobulin therapy. This treatment reduced the frequency of infectious manifestations of the disease and it did not significantly improve the course of rheumatological diseases. Therefore, the use of methotrexate and targeted therapy was continued. Conclusion: In the clinical picture of PID, rheumatic symptoms predominate in 28.6% of cases, which requires a thorough immunological and genetic examination of patients with rheumatic diseases in order to diagnose PID in a timely manner. References: [1]Picard C, Bobby Gaspar H, Al-Herz W, et al. J Clin Immunol. 2018;38(1):96-128. Disclosure of Interests: None declared
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 969
Open AccessPOS1374 RHEUMATOLOGIC DISEASES AS PRESENTATIONS OF PRIMARY IMMUNODEFICIENCY DISEASES
Background: Primary immunodeficiency diseases (PID) occur on average with a frequency of 1: 100 000 of the population. In accordance with the classification of PIDS of the International Union of Immunological Societies (IUIS) 9 different groups of innate errors of immunity are distinguished [1]. The polymorphism of the clinical picture, difficulties in recognizing PID cause their late diagnosis and the associated development of irreversible organ damage, complications and high mortality. According to the traditional view, the clinical marker of PID is an infectious syndrome. However, in some cases, PID is detected as a rheumatologic disease. Objectives: The aim of the study is to analyze the frequency of rheumatologic diseases in adult patients with PID living in one of the subjects of Russia –Chuvashia. Methods: The material of the study was patient data obtained during a retrospective analysis of 49 outpatient records included in the Republican Register of PID. Diagnosis of various forms of PIDS was carried out in accordance with the criteria developed by the IUIS [1]. Results: During the period from 1993 to January 2020, 49 cases of PID were registered in the adult population of Chuvashia. According to the frequency of PID, сommon variable immunodeficiency (CVID) is the most common in Chuvashia (26 people). In the second place there is selective IgA deficiency (10 people); in third place there are X-linked agammaglobulinemia (4 people) and hereditary angioedema (4 people). The remaining forms of PID account for 5 cases: 2 cases of Louis-Bar syndrome, 1 case of DiGeorge syndrome, 1 case of Wiskott-Aldrich syndrome and 1 case of Hyper IgE syndrome. The main symptom of PID in 35 (71.4%) patients was heightened susceptibility to infection. In 14 (28.6%) patients, the clinical picture was dominated by non-infectious presentations (autoimmune, lymphoproliferative and oncological diseases). In 9 patients (18.3%), it was manifested by rheumatologic diseases (rheumatoid arthritis, psoriatic arthritis, scleroderma-like syndrome). These symptoms were more characteristic of CVID. With selective IgA deficiency and X-linked agammaglobulinemia, rheumatic symptoms were observed only in isolated cases. CVID debuted in 2 cases as rheumatoid arthritis, resulting in the delay in the diagnosis of an average of 5.2 years. Only the detailed immunological and genetic study made it possible to diagnose PID and prescribe adequate treatment – replacement immunoglobulin therapy. This treatment reduced the frequency of infectious manifestations of the disease and it did not significantly improve the course of rheumatological diseases. Therefore, the use of methotrexate and targeted therapy was continued. Conclusion: In the clinical picture of PID, rheumatic symptoms predominate in 28.6% of cases, which requires a thorough immunological and genetic examination of patients with rheumatic diseases in order to diagnose PID in a timely manner. References: [1]Picard C, Bobby Gaspar H, Al-Herz W, et al. J Clin Immunol. 2018;38(1):96-128. Disclosure of Interests: None declared
- Open Access
- 3 May 2021
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 23 (2) , 353-368
Republican registry of primary immune deficiencies in the chuvash republic and description of postvaccinal immunity disorders in a pregnant patient with common variable immune deficiency
In recent years, primary immunodeficiencies have turned from the class of rare diseases to the category of more common disorders which may be encountered by doctors of any clinical discipline. The first case of primary immunodeficiency disorder (PID) in Chuvashia was detected in 1993. Since that time, the Department of Internal Diseases with the Course of Clinical Immunology at the I. Ulyanov Chuvash State University registered all the cases of PID diagnosed in the region, introducing them into the Republican Registry of PID. The study was aimed for searching epidemiological indexes, clinical and laboratory manifestations of PID in Chuvash region. The study was based on the patient data obtained by retrospective analysis of 85 case histories of PID patients, treated at different departments of the Republican Clinical Hospital, and the City Chuvash Pediatric Clinical Hospital of Public Health Ministry in 2000-2019, as well as on 49 outpatient records of the patients included into the Regional PID Registry. Various forms of PIDs were diagnosed according to the criteria developed by the European Society for Immunodeficiency and the Pan-American Group on Immunodeficiency (1999). The results of this study showed that the incidence of PID in the Chuivash Region is 3.4:100,000. The incidence of common variable immune deficiency (CVID), the most common form of PID in the region, was 1.58 per 100,000 population. The average age at the time of CVID diagnosis in Chuvash patients was 30.4±16.1 years, and the age of CVID debut was 11.3±15.0 years. The delay in proper diagnosis from the moment of clinical manifestation of CVID was, on average, 17.9 years in the region. At the time of CVID diagnosis, the patients showed marked decrease in the levels of 3 or 2 immunoglobulin classes (IgG and IgA), and T-helper cell contents (CD3+CD4+) in peripheral blood. Prevalence of selective IgA deficiency with сlinical symptoms was 0.83 per 100,000 population of the region, and the incidence of the asymptomatic form of this PID was 1 : 167. In patients with selective IgA deficiency, there were also disorders in the T cell system manifesting as decreased relative number of cytotoxic T-cells as well as elevated IgG and IgM levels. The age of diagnosis of X-linked agammaglobulinemia in the region was 3.5±3.0 years. In addition to disturbances of humoral adaptive immunity in children with this disease, a decrease in absolute T cell numbers was detected. In conclusion, the article describes disturbances of postvaccinal immunity in a pregnant patient with CVID, with asymptomatic clinical course, thus leading to false interpretation of the serological markers of TORCH infections and wrong strategy of pregnancy management.
- 3 May 2021
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 23 (2) , 353-368
Open AccessRepublican registry of primary immune deficiencies in the chuvash republic and description of postvaccinal immunity disorders in a pregnant patient with common variable immune deficiency
In recent years, primary immunodeficiencies have turned from the class of rare diseases to the category of more common disorders which may be encountered by doctors of any clinical discipline. The first case of primary immunodeficiency disorder (PID) in Chuvashia was detected in 1993. Since that time, the Department of Internal Diseases with the Course of Clinical Immunology at the I. Ulyanov Chuvash State University registered all the cases of PID diagnosed in the region, introducing them into the Republican Registry of PID. The study was aimed for searching epidemiological indexes, clinical and laboratory manifestations of PID in Chuvash region. The study was based on the patient data obtained by retrospective analysis of 85 case histories of PID patients, treated at different departments of the Republican Clinical Hospital, and the City Chuvash Pediatric Clinical Hospital of Public Health Ministry in 2000-2019, as well as on 49 outpatient records of the patients included into the Regional PID Registry. Various forms of PIDs were diagnosed according to the criteria developed by the European Society for Immunodeficiency and the Pan-American Group on Immunodeficiency (1999). The results of this study showed that the incidence of PID in the Chuivash Region is 3.4:100,000. The incidence of common variable immune deficiency (CVID), the most common form of PID in the region, was 1.58 per 100,000 population. The average age at the time of CVID diagnosis in Chuvash patients was 30.4±16.1 years, and the age of CVID debut was 11.3±15.0 years. The delay in proper diagnosis from the moment of clinical manifestation of CVID was, on average, 17.9 years in the region. At the time of CVID diagnosis, the patients showed marked decrease in the levels of 3 or 2 immunoglobulin classes (IgG and IgA), and T-helper cell contents (CD3+CD4+) in peripheral blood. Prevalence of selective IgA deficiency with сlinical symptoms was 0.83 per 100,000 population of the region, and the incidence of the asymptomatic form of this PID was 1 : 167. In patients with selective IgA deficiency, there were also disorders in the T cell system manifesting as decreased relative number of cytotoxic T-cells as well as elevated IgG and IgM levels. The age of diagnosis of X-linked agammaglobulinemia in the region was 3.5±3.0 years. In addition to disturbances of humoral adaptive immunity in children with this disease, a decrease in absolute T cell numbers was detected. In conclusion, the article describes disturbances of postvaccinal immunity in a pregnant patient with CVID, with asymptomatic clinical course, thus leading to false interpretation of the serological markers of TORCH infections and wrong strategy of pregnancy management.
- 25 March 2021
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 1,p. 57-65
SYSTEMIC LUPUS ERYTHEMATOSUS: REVIEW OF MODERN METHODS OF DIAGNOSIS, TREATMENT AND DESCRIPTION OF THE CLINICAL CASE
A clinical case of systemic lupus erythematosus (SLE) is presented. Since childhood the patient had preclinical lupus: leukopenia, anemia, photoallergy, vasculitis, and serological changes a-SS-A (+++), but at that time the findings did not meet the criteria for SLE. At the initial examination of the woman at the age of 24 years, a clinical blood test revealed hemoglobin 101 g/l, leukopenia 3.2×109/l, ESR 41 mm/h, hyper-γ-globulinemia 29%. The immunological blood analysis revealed a-DNA (+++), a-SS-A (+++), aSm (+++), aRNP (+++). The diagnosis was "Systemic lupus erythematosus of chronic (at the beginning) course, activity of the 1st degree (2 points by the SLEDA scale): with hematological disorders (leukopenia), immunological disorders (ANA+)". Metypred was administered at a dose of 16 mg/day, followed by the dose reduction to 6 mg/day and Plaquenil 400 mg/day. The woman received inpatient and outpatient treatment, repeatedly consulted in the Federal State Budgetary Institution "V.A. Nasonova Research Institute" under the Russian Academy of Medical Sciences. At the age of 26, the diagnosis was made: "Systemic lupus erythematosus, grade 2 activity with skin lesions of the type of subacute cutaneous lupus, cheilitis, lymphadenopathy", blood tests revealed leukopenia, lymphopenia, anemia, as well as immunological disorders: a-n DNA 93.4 u/ml, aSm > 200 u/ml, aRo > 200 u/ml, C3 0.63 g/l, rheumatoid factor 69.5 mIU/ml, ANA (Нер-2) 1/640 Sp. A complex therapy was performed with the use of Metypred, Cyclophosphane and Azathioprine. Against the background of the therapy, the patient's condition is stable, but immunological disorders are preserved: persistent high positivity for aRo-SS-A and the presence of the rheumatoid factor. The case demonstrates the need for an in-depth examination of women with anemia of unknown origin in combination with leukopenia to exclude systemic diseases of the connective tissue.
- 25 March 2021
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 1,p. 57-65
SYSTEMIC LUPUS ERYTHEMATOSUS: REVIEW OF MODERN METHODS OF DIAGNOSIS, TREATMENT AND DESCRIPTION OF THE CLINICAL CASE
A clinical case of systemic lupus erythematosus (SLE) is presented. Since childhood the patient had preclinical lupus: leukopenia, anemia, photoallergy, vasculitis, and serological changes a-SS-A (+++), but at that time the findings did not meet the criteria for SLE. At the initial examination of the woman at the age of 24 years, a clinical blood test revealed hemoglobin 101 g/l, leukopenia 3.2×109/l, ESR 41 mm/h, hyper-γ-globulinemia 29%. The immunological blood analysis revealed a-DNA (+++), a-SS-A (+++), aSm (+++), aRNP (+++). The diagnosis was "Systemic lupus erythematosus of chronic (at the beginning) course, activity of the 1st degree (2 points by the SLEDA scale): with hematological disorders (leukopenia), immunological disorders (ANA+)". Metypred was administered at a dose of 16 mg/day, followed by the dose reduction to 6 mg/day and Plaquenil 400 mg/day. The woman received inpatient and outpatient treatment, repeatedly consulted in the Federal State Budgetary Institution "V.A. Nasonova Research Institute" under the Russian Academy of Medical Sciences. At the age of 26, the diagnosis was made: "Systemic lupus erythematosus, grade 2 activity with skin lesions of the type of subacute cutaneous lupus, cheilitis, lymphadenopathy", blood tests revealed leukopenia, lymphopenia, anemia, as well as immunological disorders: a-n DNA 93.4 u/ml, aSm > 200 u/ml, aRo > 200 u/ml, C3 0.63 g/l, rheumatoid factor 69.5 mIU/ml, ANA (Нер-2) 1/640 Sp. A complex therapy was performed with the use of Metypred, Cyclophosphane and Azathioprine. Against the background of the therapy, the patient's condition is stable, but immunological disorders are preserved: persistent high positivity for aRo-SS-A and the presence of the rheumatoid factor. The case demonstrates the need for an in-depth examination of women with anemia of unknown origin in combination with leukopenia to exclude systemic diseases of the connective tissue.
- 25 September 2020
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 3,p. 7-19
IMMUNE MECHANISMS FOR THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS
Hepatorenal syndrome is a life-threatening complication of liver cirrhosis. 90% of patients with liver cirrhosis die within 2 months since the onset of hepatorenal syndrome development. For many years the hypothesis of the hemodynamic mechanism of hepatorenal syndrome development was accepted as the only true one, according to this hypothesis compensatory systemic vasodilation in response to portal hypertension causes renal ischemia and the development of functional specific acute kidney damage, the so-called “hepatorenal syndrome – acute kidney damage”. In recent years some works were published that substantiate the role of a systemic inflammatory reaction in the development of hepatorenal syndrome; this inflammatory reaction being associated with activation of innate immunity cells in response to a bacterial infection, including that to the microflora of the intestine which is adjacent to the liver. Data has been obtained which indicated that Toll-like receptors (TLRs), in particular TLR4 and TLR9 are involved in the development of hepatorenal syndrome.
- 25 September 2020
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 3,p. 7-19
IMMUNE MECHANISMS FOR THE DEVELOPMENT OF HEPATORENAL SYNDROME IN LIVER CIRRHOSIS
Hepatorenal syndrome is a life-threatening complication of liver cirrhosis. 90% of patients with liver cirrhosis die within 2 months since the onset of hepatorenal syndrome development. For many years the hypothesis of the hemodynamic mechanism of hepatorenal syndrome development was accepted as the only true one, according to this hypothesis compensatory systemic vasodilation in response to portal hypertension causes renal ischemia and the development of functional specific acute kidney damage, the so-called “hepatorenal syndrome – acute kidney damage”. In recent years some works were published that substantiate the role of a systemic inflammatory reaction in the development of hepatorenal syndrome; this inflammatory reaction being associated with activation of innate immunity cells in response to a bacterial infection, including that to the microflora of the intestine which is adjacent to the liver. Data has been obtained which indicated that Toll-like receptors (TLRs), in particular TLR4 and TLR9 are involved in the development of hepatorenal syndrome.